Non-small cell lung cancer metastatic
Not recruitingStudy Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancer metastatic
- Substances:Pembrolizumab
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Formycon AG



